产品
编 号：F150893
分子式：C26H25F3N4O7S
分子量：594.56
分子式：C26H25F3N4O7S
分子量：594.56
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
200mg
询价
询价
1g
询价
询价
5g
询价
询价
10g
询价
询价
结构图
CAS No: 1400591-39-0
产品详情
生物活性：
Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic. Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria.
体内研究：
Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo.Animal Model:Male Slc:ICR mice infected with S. aureus
Dosage:1.27-2.15 mg/kg
Administration:Oral gavage; 1.27-2.15 mg/kg; once
Result:Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.0125 μg/mL.
Animal Model:Male Slc:ICR mice infected with E. coli
Dosage:0.16-0.30 mg/kg
Administration:Oral gavage; 0.16-0.30 mg/kg; once
Result:Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.0125 μg/mL.
Animal Model:Male Slc:ICR mice infected with P. aeruginosa
Dosage:7.66-13.39 mg/kg
Administration:Oral gavage; 7.66-13.39 mg/kg; once
Result:Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.78 μg/mL.
体外研究：
Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens.
Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic. Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria.
体内研究：
Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo.Animal Model:Male Slc:ICR mice infected with S. aureus
Dosage:1.27-2.15 mg/kg
Administration:Oral gavage; 1.27-2.15 mg/kg; once
Result:Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.0125 μg/mL.
Animal Model:Male Slc:ICR mice infected with E. coli
Dosage:0.16-0.30 mg/kg
Administration:Oral gavage; 0.16-0.30 mg/kg; once
Result:Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.0125 μg/mL.
Animal Model:Male Slc:ICR mice infected with P. aeruginosa
Dosage:7.66-13.39 mg/kg
Administration:Oral gavage; 7.66-13.39 mg/kg; once
Result:Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.78 μg/mL.
体外研究：
Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备